心血管疾病抗栓治疗强化试验在真实世界患者中的可推广性
本研究将COMPASS、CHARISMA、PEGASUS-TIMI和DAPT试验的入选/排除标准应用于UCC-SMART队列中的冠状动脉疾病和/或外周动脉疾病患者,评估真实世界合格性。结果显示,CAD患者的合格率范围为11%-94%,PAD患者为75%-90%;合格与不合格患者的心血管事件、大出血和死亡风险存在差异,但校正试验入选标准后,多数调整后风险相似。结论认为,当代CVD患者中很大比例符合强化抗栓治疗试验条件,试验为基础的指南推荐基本适用于真实世界患者。
要点
- COMPASS、CHARISMA、PEGASUS-TIMI和DAPT试验标准在真实世界CAD/PAD患者中的合格率为11%-94%。
- 合格与不合格患者的事件风险存在差异,但校正后多数调整风险相似。
- 试验为基础的指南推荐对真实世界CVD患者大多适用。
核心结论
- 当代CVD患者中很大比例符合强化抗栓治疗试验条件。
- 合格与不合格患者的事件风险多数在调整后相似。
- 试验为基础的指南推荐基本适用于真实世界患者。
研究设计与样本
- 将COMPASS、CHARISMA、PEGASUS-TIMI和DAPT试验的入选和排除标准应用于UCC-SMART队列中的CAD和/或PAD患者。
- 比较合格与不合格患者的基线特征、心血管事件、大出血和死亡率。
主要发现
- CAD患者的合格率范围为11%-94%,PAD患者为75%-90%。
- COMPASS合格的CAD患者心血管、出血和死亡风险率比分别为1.98(95%CI 1.74-2.26)、2.02(95%CI 1.47-2.78)和3.11(95%CI 2.71-3.57)。
- CHARISMA合格患者心血管、出血和死亡风险率比分别为1.51(95%CI 1.12-2.06)、2.25(95%CI 1.01-6.21)和4.43(95%CI 2.79-7.51)。
- COMPASS合格的PAD患者心血管、出血和死亡风险率比分别为0.45(95%CI 0.36-0.56)、0.29(95%CI 0.18-0.46)和0.45(95%CI 0.38-0.54)。
- DAPT合格的CAD患者心血管风险率比0.49(95%CI 0.34-0.69),死亡风险率比0.67(95%CI 0.48-0.94)。
临床怎么用
- 试验为基础的指南推荐可考虑应用于真实世界CVD患者。
- 需注意合格与不合格患者的事件风险差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Assessment of generalisability of guideline-informing trials on antithrombotic treatment intensification to real-world patients with cardiovascular disease (CVD). METHODS: Inclusion and exclusion criteria of the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS), Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA), Prevention of Cardiovascular events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction (PEGASUS-TIMI) and Dual Antiplatelet Therapy (DAPT) study were applied to coronary artery disease (CAD) and/or peripheral artery disease (PAD) patients from Utrecht Cardiovascular Cohort-Second Manifestations of Arterial Disease (UCC-SMART) to determine real-world eligibility. Eligible and ineligible patients were compared on baseline characteristics, cardiovascular events, major bleeding and mortality. RESULTS: Eligibility ranged from 11%-94% for CAD to 75%-90% for patients with PAD. Cardiovascular, bleeding and mortality risks were higher in COMPASS-eligible patients with CAD (rate ratios (RR) 1.98 (95% CI 1.74 to 2.26), 2.02 (95% CI 1.47 to 2.78) and 3.11 (95% CI 2.71 to 3.57), respectively) and CHARISMA-eligible patients (RR 1.51 (95% CI 1.12 to 2.06), 2.25 (95% CI 1.01 to 6.21) and 4.43 (95% CI 2.79 to 7.51), respectively), and lower in COMPASS-eligible patients with PAD (RR 0.45 (95% CI 0.36 to 0.56), 0.29 (95% CI 0.18 to 0.46) and 0.45 (95% CI 0.38 to 0.54), respectively) and DAPT-eligible patients with CAD (RR CVD 0.49 (95% CI 0.34 to 0.69) and mortality 0.67 (95% CI 0.48 to 0.94)) than ineligible patients. After adjustment for trial eligibility criteria, only higher cardiovascular and mortality risks in COMPASS-eligible patients with CAD and lower cardiovascular risks in CHARISMA-eligible and DAPT-eligible patients persisted with CAD. CONCLUSION: A large proportion of contemporary CVD patients would be eligible for intensified antithrombotic treatment trials, with mostly similar adjusted event risks to ineligible patients. Trial-based guideline recommendations are largely applicable to real-world patients.
引用
- Castelijns MC, Hageman SHJ, Teraa M, et al. Generalisability of trials on antithrombotic treatment intensification in patients with cardiovascular disease. Heart. 2024. PMID: 38182277. doi:10.1136/heartjnl-2023-323519
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。